On the stock market since 2020, it operates in the world of health and science. It has 56 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 17% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 67% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 31% a year on average.
Sales run at $4.7M a year. A small number, but proof the product has real buyers.
There is $278.9M in the vault; even if every debt were paid off, $259.3M would remain.
A loss of $109.7M against $4.7M in annual sales. And on top of that, sales fell from the year before.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 14/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 19/100.
On our five-subject report card, PRTC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PRTC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (19/100) says the stock isn’t cheap.